Compare FRMM & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRMM | CLNN |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.8M | 57.6M |
| IPO Year | 2017 | 2021 |
| Metric | FRMM | CLNN |
|---|---|---|
| Price | $2.26 | $3.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | $11.00 | ★ $32.20 |
| AVG Volume (30 Days) | ★ 146.1K | 93.0K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,547,000.00 | $200,000.00 |
| Revenue This Year | $177.58 | $25.30 |
| Revenue Next Year | $587.83 | $9,184.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.76 | $3.02 |
| 52 Week High | $7.15 | $10.84 |
| Indicator | FRMM | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 25.62 | 51.19 |
| Support Level | $1.76 | $3.78 |
| Resistance Level | $3.17 | $4.05 |
| Average True Range (ATR) | 0.34 | 0.37 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 7.41 | 30.19 |
Forum Markets Inc is a financial technology company focused on developing infrastructure that supports the origination, financing, and distribution of RWAs through blockchain-enabled capital markets. The company's business approach is centered on integrating traditional financial asset markets with blockchain-based infrastructure to enable the tokenization of income-generating real-world assets such as consumer credit, equipment finance assets, and other contractual cash-flow streams. It utilizes blockchain infrastructure, including Ethereum and related Layer-2 scaling protocols, to support the issuance, management, and potential secondary trading of tokenized financial instruments.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.